| GeneLibs

题目:: New cell sources for T cell engineering and adoptive immunotherapy.
作者:: Themeli(Maria),Rivière(Isabelle),Sadelain(Michel)
状态:: 发布时间2015-04-06 , 更新时间 2016-05-18
期刊:: Cell Stem Cell
摘要:: The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products.
语言:: eng
DOI:: 10.1016/j.stem.2015.03.011

文献库文献相关信息